AcouSort recieves top rating from Eurostars for project on stem cells for regenerative therapy
The project Blue4Therapy, where AcouSort is a co-applicant, is ranked number 17 among 449 candidates applying for Eurostars funding. If the project is funded, AcouSort will be able to accelerate the development of the company’s technology for clinical applications within cell therapy and stem cell treatments. These are application areas with great commercial potential.
The goal of the project is to develop a platform for separation of specific stem cells called Blue Cells. These are found in adipose tissue and can be used to treat different medical diseases. The project is planned to run over two years and generate revenue of EUR 300 000 to AcouSort. The final decision on whether the project will recieve funding will be announced by Eurostars no later than July.
Behind the project is a consortium consting of Syddansk Universitet and its spin-off company Regenerative Therapeutics, together with AcouSort and the Danish company Novozymes. Regererative Technology has patented the use of the specific cells for regenerative therapy of several diseases. The initial disease areas are erectile dysfuntion and lymphedema caused by treatment of prostate and breast cancer, respectively.
The full press release can be found here (Swedish)